Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Shandong Xinhua Pharma
Pharmaceutical Preparation ManufacturingChinaHKSE: 0719.HK
Last verified 5 months agoxhzy.com
**Shandong Xinhua Pharmaceutical Co., Ltd.** (Xinhua Pharma) is a leading force in the global pharmaceutical preparation manufacturing industry. Established in 1943, this esteemed Chinese enterprise, headquartered in Zibo, Shandong Province, with significant operational reach across Asia and beyond, has consistently driven innovation in healthcare for over eight decades.
As a pioneer in pharmaceutical development, Xinhua Pharma specialises in the research, development, manufacturing, and distribution of a comprehensive range of active pharmaceutical ingredients (APIs), pharmaceutical preparations, and intermediates. Their distinctive portfolio includes analgesics, antipyretics, cardiovascular medications, and central nervous system drugs, all produced to stringent international quality standards.
Xinhua Pharma’s commitment to scientific advancement and patient well-being has positioned it as a trusted partner in the healthcare sector. Their extensive history of excellence and continuous innovation underscore their dedication to delivering high-quality, effective medical solutions worldwide.
38
DitchCarbon score
-4 vs industry average
Shandong Xinhua Pharma’s score of 38 is lower than 49% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Shandong Xinhua Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very High
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Shandong Xinhua Pharma's reported carbon emissions
In 2025, Shandong Xinhua Pharmaceutical Co., Ltd reported total carbon emissions of approximately 909.6 million kg CO2e. This figure includes Scope 1 emissions of about 325,250 kg CO2e, Scope 2 emissions of approximately 282.1 million kg CO2e, and Scope 3 emissions of around 627.2 million kg CO2e.
The company has committed to near-term climate targets, although specific reduction targets have not been detailed. As of December 2025, Shandong Xinhua Pharma is classified as "Committed" to near-term targets under the Science Based Targets initiative (SBTi).
Over the previous years, emissions have shown fluctuations, with 2024 emissions recorded at approximately 307.6 million kg CO2e (Scope 1: about 22.1 million kg CO2e, Scope 2: approximately 285.6 million kg CO2e) and 2023 emissions at around 260.6 million kg CO2e (Scope 1: about 18.9 million kg CO2e, Scope 2: approximately 241.7 million kg CO2e).
Shandong Xinhua Pharma's emissions data is not cascaded from any parent company, indicating that the reported figures are independently sourced. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector in China, reflecting its commitment to addressing climate change through potential future initiatives.
Assessing Shandong Xinhua Pharma as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Shandong Xinhua Pharma and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Shandong Xinhua Pharma’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
On track94%
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
At risk48%
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Behind target22%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Shandong Xinhua Pharma5 months ago
38
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Shandong Xinhua Pharma’s sustainability data and climate commitments
In 2025, Shandong Xinhua Pharma reported total carbon emissions of approximately 909.6 million kg CO2e. This comprehensive figure includes Scope 1 emissions of about 325,250 kg CO2e, Scope 2 emissions totaling around 282.1 million kg CO2e, and a significant portion from Scope 3 emissions, which were approximately 627.2 million kg CO2e. This data reflects the company's direct and indirect environmental impact within the Pharmaceutical Preparation Manufacturing sector in China.
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more